TENX Tenax Therapeutics
- 3.5490
- -0.0010-0.03%
Tenax Therapeutics News
Tenax Therapeutics | 10-Q: Quarterly report
Tenax Therapeutics Q1 EPS $(3.12) Misses $(2.40) Estimate
Tenax Therapeutics (NASDAQ:TENX) reported quarterly losses of $(3.12) per share which missed the analyst consensus estimate of $(2.40) by 30 percent. This is a 74 percent increase over losses of $(12.
Tenax Therapeutics 1Q Loss/Shr $3.12 >TENX
Tenax Therapeutics 1Q Loss/Shr $3.12 >TENX
Press Release: Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update Currently Enrolling Patients in Phase 3 LEVEL Study with 24 Investigative Sites Initiated Secured Glob
Tenax Therapeutics Announces New US Patent Covering The Use Of Levosimendan In Pulmonary Hypertension With Heart Failure With Preserved Ejection Fraction, The New Patent Provides Protections Through December 2040
Tenax Therapeutics Announces New US Patent Covering The Use Of Levosimendan In Pulmonary Hypertension With Heart Failure With Preserved Ejection Fraction, The New Patent Provides Protections Through D
Hearing Tenax Therapeutics To Be Issued U.S. Patent Titled 'LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION'
Hearing Tenax Therapeutics To Be Issued U.S. Patent Titled 'LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION'
Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of Alcoa Corporation (NYSE:AA) rose sharply in today's pre-market trading after the company reported better-than-expected sales for its first quarter. The company reported quarterly losses of
Tenax Therapeutics to Host KOL Event: "LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study"
Presentations from four globally recognized experts in the field of heart failure will explore this most prevalent type of pulmonary hypertension and the therapeutic potential of levosimendan:
Tenax Therapeutics: Q4 Earnings Insights
Tenax Therapeutics (NASDAQ:TENX) reported its Q4 earnings results on Thursday, March 28, 2024 at 08:30 AM.Here's what investors need to know about the announcement.EarningsTenax Therapeutics missed es
Tenax Therapeutics Q4 EPS $(11.84) Misses $(8.14) Estimate
Tenax Therapeutics (NASDAQ:TENX) reported quarterly losses of $(11.84) per share which missed the analyst consensus estimate of $(8.14) by 45.45 percent. This is a 83.74 percent increase over losses o
Tenax Therapeutics GAAP EPS of -$31.04
Tenax Therapeutics 2023 Loss $7.7M >TENX
Tenax Therapeutics 2023 Loss $7.7M >TENX
Tenax Therapeutics to Present at the 36th Annual Roth Conference
CHAPEL HILL, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that
Tenax Therapeutics Meets Nasdaq's Float Requirement Compliance
Roth MKM Reiterates Buy on Tenax Therapeutics, Maintains $30 Price Target
Roth MKM analyst Jonathan Aschoff reiterates Tenax Therapeutics (NASDAQ:TENX) with a Buy and maintains $30 price target.
Tenax Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/20/2024 644.44% Roth MKM → $30 Reiterates Buy → Buy 11/13/2023 48.89% Roth MKM → $6 Reiterates Buy → Bu
Tenax Secures Global Rights for Heart Treatment Drug
Tenax Therapeutics Announces Amendment To Existing Exclusive License Agreement With Orion Corporation, Expanding Tenax's Territory Rights From North America To The Entire World
Tenax Therapeutics Announces Amendment To Existing Exclusive License Agreement With Orion Corporation, Expanding Tenax's Territory Rights From North America To The Entire World
Tenax Therapeutics 13G Filing Shows CVI Investments, Inc. Reported A 9.9% Stake In The Co As Of February 8, 2024
Tenax Therapeutics 13G Filing Shows CVI Investments, Inc. Reported A 9.9% Stake In The Co As Of February 8, 2024
Tenax Therapeutics Raises $9M in Public Offering and Warrants
Analysis
Price Target
No Data
